Clinical Trial Update: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating navitoclax in combination with ruxolitinib versus ruxolitinib alone in adults with myelofibrosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Navitoclax (navitoclax)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: AbbVie | Conditions: Myelofibrosis (MF) | Phase 3 | Status: COMPLETED | Results posted: 2026-03-23